Take­da earns win for its TKI in­hibitor in tiny lung can­cer group — but GI side ef­fects could be an ear­ly red flag

Japan­ese drug­mak­er Take­da has made a big push in re­cent years to build a hand in on­col­o­gy, par­tic­u­lar­ly in the next-gen can­cer space. One of those can­di­dates, ty­ro­sine ki­nase in­hibitor (TKI) mobo­cer­tinib, re­cent­ly earned the FDA’s in­ter­est in a small sec­tion of un­treat­ed lung can­cer pa­tients, but will se­vere GI side ef­fects be a road­block?

Take­da’s oral mobo­cer­tinib post­ed clin­i­cal­ly sig­nif­i­cant ob­jec­tive re­sponse rates in a Phase I/II adap­tive tri­al drug­ging metasta­t­ic non-small cell lung can­cer pa­tients with EGFR ex­on 20 gene mu­ta­tions who had pre­vi­ous­ly un­der­gone plat­inum-based chemother­a­py, ac­cord­ing to da­ta pre­sent­ed Thurs­day at the vir­tu­al World Con­fer­ence on Lung Can­cer.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER